Kyverna Therapeutics, Inc.
NASDAQ:KYTX · NASDAQ Global Select
-$0.12 today
Vol 1.11M · Avg 0.94M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$161.3M -26.5% | -$127.5M -111.2% | -$60.4M -108.9% | -$28.9M -9.7% | -$26.4M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $1.8M -15.7% | $2.1M +25.0% | $1.7M +62.4% | $1.1M +79.4% | $586.0K | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $10.1M +20.6% | $8.4M +276.4% | $2.2M +139.0% | $929.0K -87.2% | $7.3M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$1.1M -113.7% | $7.9M +129.5% | $3.4M +133.2% | -$10.3M -129.9% | -$4.5M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | $0 | $0 | $0 | $0 | $0 | $592.6M | $1.3B | $626.2M |
| Inventory | $0 | $0 | $0 | $0 | $0 | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $543.0K -26.2% | $736.0K -82.0% | $4.1M +503.1% | $677.0K +6054.5% | $11.0K | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$1.6M -122.7% | $7.1M +1180.6% | -$659.0K +94.0% | -$11.0M -144.4% | -$4.5M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | -$3.2M +37.3% | -$5.1M -946.3% | $605.0K -46.3% | $1.1M +32.6% | $850.0K | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$153.7M -34.5% | -$114.3M -118.0% | -$52.4M -45.1% | -$36.1M -63.0% | -$22.2M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$5.0K +99.8% | -$2.2M -255.1% | -$621.0K +19.1% | -$768.0K +40.4% | -$1.3M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $70.0K | $0 | $0 | $0 | $0 | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$364.6M +25.6% | -$490.0M -793.4% | -$54.8M +2.9% | -$56.5M | $0 | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $398.8M +23.2% | $323.6M +593.3% | $46.7M +8.1% | $43.2M | $0 | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $5.8M -24.8% | $7.7M | $0 | $0 | $0 | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | $40.0M +124.9% | -$160.9M -1731.6% | -$8.8M +37.7% | -$14.1M -993.6% | -$1.3M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $23.9M +2599.2% | -$956.0K -22.4% | -$781.0K -213.7% | -$249.0K -507.3% | -$41.0K | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $117.4M -65.6% | $341.2M | $0 | $0 | $0 | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$144.0K +95.4% | -$3.1M -209.9% | -$1.0M -672.0% | $175.0K +483.3% | $30.0K | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $141.2M -58.1% | $337.1M +480.0% | $58.1M +389.2% | $11.9M -83.6% | $72.5M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $0 | $0 | $0 | $0 | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $27.5M -55.7% | $62.0M +2113.7% | -$3.1M +92.0% | -$38.3M -178.1% | $49.1M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$153.7M -32.0% | -$116.5M -119.6% | -$53.0M -43.8% | -$36.9M -57.3% | -$23.4M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Capricor Therapeutics, Inc.
NASDAQ:CAPR
$1.29B
Allogene Therapeutics, Inc.
NASDAQ:ALLO
$484.08M
Cabaletta Bio, Inc.
NASDAQ:CABA
$468.78M
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNM
$438.73M
Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEO
$386.33M
Atea Pharmaceuticals, Inc.
NASDAQ:AVIR
$343.72M
Silence Therapeutics plc
NASDAQ:SLN
$324.02M
Lyell Immunopharma, Inc.
NASDAQ:LYEL
$294.28M
Editas Medicine, Inc.
NASDAQ:EDIT
$253.51M
Mereo BioPharma Group plc
NASDAQ:MREO
$50.71M
SEC Filings
Recent regulatory filings
No filings found.
Does KYTX generate free cash flow?
Kyverna Therapeutics, Inc. (KYTX) generated -$153,717,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does KYTX produce?
Operating cash flow was -$153,712,000.00, before capital expenditures of $5,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.